Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Clin Genitourin Cancer. 2021 Dec 17;20(2):165–175. doi: 10.1016/j.clgc.2021.12.012

Table 1.

Baseline characteristics for patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors, stratified by treatment line and prior history of BCG

First line ICI Second or later line ICI
History of BCG No Yes P No Yes P
Number of Patients 287 78 205 75
Age at ICI initiation, median (IQR) 70 (67–82) 69 (49–79) 0.22 66 (59–80) 77 (60–82) <0.001
Sex, N (%)
Male 206 (72) 63 (81) 0.11 154 (75) 66 (88) 0.02
Female 81 (28) 15 (20) 51 (25) 9 (12)
Smoking History, N (%)
Ever Smoker 204 (72) 49 (63) 0.12 148 (72) 51 (68) 0.49
Never Smoker 80 (28) 29 (37) 57 (28) 24 (32)
Race, N (%)
White race 216 (75) 61 (78) 0.85 151 (74) 57 (76) 0.04
Hispanic 31 (11) 6 (8) 31 (15) 4 (5)
African American 16 (6) 4 (5) 12 (6) 5 (7)
Asian 8 (3) 4 (5) 8 (4) 3 (4)
Histology, N (%)
Pure UC 188 (66) 56 (72) 0.31 157 (77) 57 (76) 0.87
Mixed UC 98 (34) 22 (28) 47 (23) 18 (24)
Non-UC 1 (0) 0 (0) 1 (0) 0 (0)
Prior platinum chemotherapy, N (%)
No 148 (52) 52 (67) 0.018 14 (7) 3 (4) 0.38
Yes 139 (48) 26 (33) 191 (93) 72 (96)
Albumin<3.5 g/dL at ICI initiation, N (%)
No 96 (33) 24 (31) 0.48 63 (31) 32 (43) 0.07
Yes 171 (60) 52 (67) 131 (64) 40 (53)
Hgb<10 g/dL at ICI initiation, N (%)
No 212 (74) 53 (68) 0.29 144 (70) 60 (80) 0.14
Yes 68 (24) 23 (30) 55 (27) 14 (19)
Liver Metastasis at ICI initiation, N (%)
No 249 (87) 63 (81) 0.18 156 (76) 57 (76) 0.99
Yes 38 (13) 15 (19) 49 (24) 18 (24)
ECOG Performance Status, N (%)a
0 57 (20) 18 (23) 0.67 36 (18) 18 (24) 0.58
1 131 (46) 32 (41) 119 (58) 40 (53)
2 69 (24) 18 (23) 24 (12) 11 (15)
3 6 (2) 3 (4) 5 (2) 1 (1)
4 1 (0) 1 (1) 0 (0) 0 (0)
Missing 23 (8) 6 (8) 21 (10) 5 (7)
ICI Received, N (%)
Atezolizumab 113 (39) 30 (39) 0.37 110 (54) 44 (60) 0.18
Avelumab 1 (0) 0 (0) 1 (<1) 0 (0)
Durvalumab 7 (2) 4 (5) 6 (3) 1 (1)
Nivolumab 16 (6) 1 (1) 26 (13) 4 (6)
Pembrolizumab 147 (51) 42 (54) 60 (30) 24 (33)
Risk Scoreb
0 112 (39) 24 (31) 0.62 27 (13) 11 (15) 0.27
1 83 (29) 22 (28) 83 (41) 38 (51)
2 37 (13) 12 (15) 59 (29) 19 (25)
3c 26 (9) 7 (10) 12 (6) 1 (1)
Missing 28 (10) 12 (16) 24 (11) 6 (8)
a

At time of ICI initiation

b

First-line: Internally developed risk score, Ali risk model (ECOG PS, liver mets, NLR, albumin) [13]; Second or later line: Bellmunt risk score (ECOG, liver mets, Hgb) [14]

c

First-line risk score includes four factors thus score of 3 is ≥3